• Tues news: Prostate cancer trials to watch. Merck’s subcutaneous Keytruda. Apellis sees positive in Astellas CRL. Future of Medicare price negotiations. JNJ psoriasis results. See more on our front page

patterson fuse

























































Fuse is garbage and will never make it to market in any meaningful way. We should have cut our losses years ago and jettisoned the whole team. Patterson is not a cloud software company. We shouldn't be pretending we are. Even if this makes it to market, it will never turn a profit.